Medical Diagnostic Developer MELA Sciences to Present at SeeThruEquity Microcap Conf. Feb. 6 in NYC and to Exhibit at Maui Dermatology Conf. Jan. 26-30 Presentation Audio and Slides Available Live and Via Webcast Business Wire NEW YORK -- January 27, 2014 MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind^®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced its CEO, Rose Crane, will present at the SeeThruEquity Winter Microcap Investor Conference on February 6, 2014 at 9:30 am ET in New York. Ms. Crane; Robert Coradini, Chairman; Mary Phellan, Controller; and Diana Garcia Redruello, head of the MelaFind Commercial Team will be available for one-on-one meetings that day. Ms. Crane will review the Company’s refocused go-to-market strategy for MelaFind^®, including its sales and marketing efforts targeting leading medical dermatologists in the U.S. and Europe. Access to the webcast and presentation will be available live during the conference at 9:30am EST on February 6, 2014 via the following links: Live Audio Webcast: MELA Sciences' Webcast Presentation Slides: MELA Sciences' Corporate Presentation MELA Sciences will also be participating at the 10^th Annual Maui Derm Conference at the Grand Wailea Hotel, January 26 – 30, 2014. The conference is designed to increase physicians’ knowledge of developments in both medical and cosmetic dermatology. MELA will exhibit four clinical posters at the event as well as host a MelaFind^® workshop on Sunday, January 26. Dr. Monica Scheel, who recently presented new real-world clinical data at MELA Sciences’ Clinical Advisory meeting at the Winter Clinical Dermatology Conference – Hawaii^® last week, will host the workshop. Please follow us: Twitter: @MELASciencesIR or @MelaFind StockTwits: @MELASciencesIR Facebook: www.facebook.com/MelaFind About MELA Sciences, Inc. www.melasciences.com MELA Sciences is a medical device company developing dermatology diagnostics utilizing state-of-the-art optical imaging. The flagship product is MelaFind^®, an FDA, PMA and CE Mark approved, non-invasive diagnostic tool to aid dermatologists in melanoma evaluation and diagnosis. MelaFind^® uses a variety of visible to near-infrared light waves to evaluate skin lesions from the surface to 2.5 mm beneath the skin. It provides images and data on the relative disorganization of a lesion's cell structure that provides substantial additional perspective to aid melanoma diagnosis. MELA is also exploring new potential uses for its core imaging technology and algorithms. Contact: Media MELA Sciences, Inc. Diana Garcia Redruello, 914-591-3783 email@example.com or Investors Catalyst Global Toni Trigiani David Collins 212-924-9800 firstname.lastname@example.org
Medical Diagnostic Developer MELA Sciences to Present at SeeThruEquity Microcap Conf. Feb. 6 in NYC and to Exhibit at Maui
Press spacebar to pause and continue. Press esc to stop.